Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ovarian germ cell tumor
Results 1-25 of 68 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG-S1316, NCT02270450
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
Pralatrexate and Carboplatin in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-113, NCI-2011-00045, NCT01188876
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
Iodine I 124 NM404 in Patients with Advanced Solid Malignancies
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: CO12901, NCI-2012-01953, 2012-0230-CP009, NCT01662284
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, P131392, NCT02054104
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 03909, NCI-2009-01467, NCT01037790
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Metformin Hydrochloride in Preventing Relapse in Patients with Stage IIC/III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Age: 19 to 79
Trial IDs: HUM00047900, NCI-2012-00384, HUM 47900, UMCC 2011.037, NCT01579812
Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients with Gynecological Cancer after Undergoing Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Tissue collection/Repository
Age: 18 and over
Trial IDs: MC1267, NCI-2013-00866, NCT01867606
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 77
Trial IDs: UC IRB13-1235, NCI-2014-00860, IRB13-1235, NCT02122185
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Randomized Clinical Trial of Skin Closure with Staples versus Suture in Reducing Complications after Surgery in Patients with BMI of 30 or Greater
Phase: Phase II
Type: Supportive care
Age: 18 to 85
Trial IDs: 201304058, NCI-2013-01279, NCT01977612
Camptothecin-20(S)-O-Propionate Hydrate in Treating Patients With Advanced Solid Tumor or Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INST CZ48-01, NCI-2011-02688, NCT00947739
Z-endoxifen Hydrochloride in Treating Patients with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0061, NCI-2013-01475, 110061, P10725, 8826, NCT01273168
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA216-001, NCI-2011-01334, NCT01292655
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-09138, NCI-2011-00920, NCT01376505
Start Over